83 results about "Solid oral dosage form" patented technology

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-to-use industrialized premixture that does not require reconstitution or dilution prior to administration to a patient. The vigabatrin liquid pharmaceutical composition is stable six months or longer at room temperature and has levels of total impurities and Vigabatrin-related compound A that are both not more than 0.04% at, or prior to, six months. In some embodiments, the composition has improved stability and patient compliance. In some embodiments, the compositions may be advantageous for the patients having swallowing difficulties or when the patients are unable to take solid oral dosage forms. In some embodiments, the composition improves compliance with ketogenic diet.

The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-to-use industrialized premixture that does not require reconstitution or dilution prior to administration to a patient. The vigabatrin liquid pharmaceutical composition is stable six months or longer at room temperature and has levels of total impurities and Vigabatrin-related compound A that are both not more than 0.04% at, or prior to, six months. In some embodiments, the composition has improved stability and patient compliance. In some embodiments, the compositions may be advantageous for the patients having swallowing difficulties or when the patients are unable to take solid oral dosage forms. In some embodiments, the composition improves compliance with ketogenic diet.

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and / or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and / or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic / methacrylic / ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

A combination therapy including both intranasal and oral solid-form preparations is described. In combination, the intranasal and oral delivery pathways provided an enhancement in appetite suppression and associated weight loss in comparison to either intranasal or oral solid-form therapy alone. It was unexpected that the observed substantial increase and increase in rate of weight loss would be observed for the combination therapy, which on average provided a nearly 12% reduction in total body weight over the three-month trial.

Pharmaceutical formulations, in particular solid oral dosage forms (e.g., tablets), comprising (i) a compound of Formula I in an amount of from about 40 wt% to about 70 wt%, (ii) a filler, (iii) a disintegrant, (iv) and a lubricant, and their uses are disclosed.

Provided herein are solid amorphous dispersions, compositions, and solid oral dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise a polymer excipient, and optionally a crystallization inhibiting polymer. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and / or inflammatory disease / disorder.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg / mL for the treatment of attention-deficit / hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg / mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence. The invention further provides scalable manufacturing methods, quality control specifications, and methods of use for treating ADHD, offering a stable, safe, and patient-friendly alternative to solid oral dosage forms.

Disclosed herein are pharmaceutical oral solid dosage forms comprising a salt of liothyronin and a salt of levothyroxine, and methods of making and using the pharmaceutical oral solid dosage forms.

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and / or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and / or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic / methacrylic / ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

This invention provides methods, systems and devices for personal, secure authenticated provision of oral solid dosage forms, administered as a dosage regimen which may be altered over time. The methods and systems rely on providing a device for personal secure administration of oral solid dosage forms to a subject, where the device comprises a plurality of individually addressable oral dosage forms contained therein, wherein a first oral dosage form of the plurality contained therein differs from that of at least a second oral dosage form of the plurality, in terms of an active ingredient type, an active ingredient dosage, or a composition component of said solid oral dosage form, or any combination thereof and wherein the device provides for dispensing at least one individually addressable oral dosage form contained therein following a personal authentication protocol and wherein the device is subject to programming, which programming controls distribution of said oral dosage forms contained therein according to a first secure distribution program and wherein the device comprises a user interface and optionally at least one sensor and wherein subject response data, sensor collected data, or testing result data or any combination thereof is collected and incorporated in the programming; and_whereby the programming controls adjusting, altering or overwriting the first distribution program via a secure protocol to a second distribution program, as a function of the collected subject response data, sensor collected data, or testing result data or any combination thereof and completing an authentication protocol for dispensing the oral dosage form to the subject and dispensing the first oral dosage form within an oral cavity of the subject and following secure communication with an authorized provider,enabling adjustment, alteration or overwriting of the programming to activate the second oral dosage form distribution program in the device; and_dispensing the oral dosage forms of the second oral dosage form distribution program to the subject, whereby an oral dosage form regimen is adjusted, altered or overwritten in the device resulting in altering dispensing of the oral dosage form, by means of a secure authenticated protocol.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention relates to the pharmaceutical compositions comprising nor-UDCA or pharmaceutically acceptable salt or ester thereof and the process for preparation. The present invention most preferably discloses the solid oral dosage form of nor-UDCA preferably in the form of tablets, capsules, disintegrating tablets and effervescent tablets.

The present invention relates to a solid, orally administrable pharmaceutical composition of resmetirom with one or more pharmaceutically acceptable excipients. More specifically a solid, orally administrable pharmaceutical composition may be prepared by a wet granulation process for preparing granules that are subsequently converted into solid oral dosage forms of resmetirom.

Pharmaceutical formulations, particularly solid oral dosage forms (e.g., tablets) comprising (i) the compound of Formula I in an amount of about 40 wt % to about 70 wt %, (ii) a filler, (iii) a disintegrating agent, (iv) and a lubricant are disclosed, as are uses thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present disclosure provides a solid oral dosage form comprising bicotegravir, or a pharmaceutically acceptable salt thereof, and lenacavir, or a pharmaceutically acceptable salt thereof.

An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg / mL for the treatment of attention-deficit / hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg / mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence. The invention further provides scalable manufacturing methods, quality control specifications, and methods of use for treating ADHD, offering a stable, safe, and patient-friendly alternative to solid oral dosage forms.

The present disclosure relates to drug-containing particles comprising one or more cannabinoids and a porous solid carrier. In embodiments, the one or more cannabinoids are adsorbed onto and / or in a porous solid carrier. In embodiments, the drug-containing particles exhibit improved solubility and bioavailability, among other beneficial properties. Methods of preparation and pharmaceutical compositions are also described.

The present invention relates to an oral solid dosage form comprising ticagrelor as pharmaceutically active ingredient and at least one excipient. In particular, the present invention relates to a process for producing an immediate release ticagrelor tablet composition which is wet granulated with croscarmellose sodium or sodium starch glycolate as a disintegrant in order to produce stable in vitro dissolution profile throughout the shelf-life.

The oral solid dosage form of the present invention comprises ruxolitinib or its pharmaceutically acceptable salts thereof, and at least one excipient. Specifically, it involves an immediate-release tablet containing the ruxolitinib salt, as well as a method for preparing this dosage form via direct compression. This method is designed to offer simplified manufacturing processes and ensure long-term stability of the product.

Provided herein are solid oral dosage forms, methods, and kits useful, e.g, for the extension of the residence time of active pharmaceutical agents in vivo by the synthesis of a polymer in situ in a subject. In particular, the solid oral dosage forms, methods, and kits disclosed herein are particularly useful for drugs that require more than once daily administration (e.g, drugs that have short half-lives).

Apparatus and methods for spectral analysis of a sample are described, for example for carrying out Raman or other optical or spectroscopic analysis of samples such as pharmaceutical dosage forms, including oral solid dosage forms such as tablets or capsules. Such apparatus may comprise delivery optics arranged to direct probe light to a delivery region of the sample, collection optics arranged to collect probe light scattered from a collection region of the sample, and a spectrometer having an entrance port, the spectrometer being arranged to receive the collected probe light from the collection optics at the entrance port of the spectrometer, and to detect spectral features in the received probe light. In particular, the collection optics may comprise Koehler integration optics arranged to process the collected probe light such that the collected light from each point of the collection region is distributed across the entrance port of the spectrometer.

Pharmaceutical compositions of ketamine derivatives and oral dosage forms comprising the pharmaceutical compositions are disclosed. Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

This invention relates to novel pharmaceutical formulations, including solid oral dosage forms containing the non-psychoactive cannabidiol (CBD). The invention also relates to methods for preparing the pharmaceutical formulation and its application in treating diseases and conditions.

The present invention provides a solid oral dosage form comprising tenofovir alafenamide, or a pharmaceutically acceptable salt thereof, and emtricitabine, or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present disclosure relates to solid oral dosage forms comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.